By Colin Kellaher

Codiak BioSciences Inc. on Tuesday said it agreed to sell its exosome manufacturing plant in Lexington, Mass., to Swiss life-sciences company Lonza Group AG.

Codiak, a Cambridge, Mass., clinical-stage biopharmaceutical company, said it will receive about $65 million worth of exosome manufacturing services for its clinical programs for four years from Lonza as consideration for the purchase.

Codiak said it will also grant Lonza a worldwide, exclusive and sub-licensable license to its high-throughput exosome manufacturing intellectual property in the contract development and manufacturing field.

Codiak added that it will retain its pipeline of therapeutic candidates, as well as its exosome engineering and drug-loading technologies.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

11-02-21 0843ET